comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 15:23:00 - browse：2652

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Dog Aging Project founders on what lies ahead after losing funding

Wikipedia

entertainment

WSS

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Gene therapy denied for Afghan refugee whose father aided U.S.

FDA sets aggressive timeline for overhauling inspection procedures

Mass General, Mayo Clinic look to monetize custom

Hospital chaplains balance Covid safety with patients’ spiritual needs

Maisha Meds is a PBM, but don't call it that

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Medical records are filled with copy

Prior authorization reform is both possible and imperative

Hepatitis C has a cure — but many Americans still lack access to it

Medicare drug price lawsuits could be good politics for Biden

After affirmative action ruling, medical educators look to 'holistic review'

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

The high cost of giving birth even with insurance

Life science postdocs should get big pay hike, NIH panel says

In Memoriam: Notable people who died in 2023

Study suggests new cause of Down syndrome: cells linked to aging

hotspot

Study suggests new cause of Down syndrome: cells linked to aging

Flu vaccine reformulation won't be easy, manufacturers warn

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Dog Aging Project founders on what lies ahead after losing funding

Physician assistants need a new name. Here's what it should be

Does Paxlovid work in people vaccinated against Covid

entertainment

Wikipedia

entertainment

focus